IL229506B - Dry powder vancomycin compositions and associated methods - Google Patents

Dry powder vancomycin compositions and associated methods

Info

Publication number
IL229506B
IL229506B IL229506A IL22950613A IL229506B IL 229506 B IL229506 B IL 229506B IL 229506 A IL229506 A IL 229506A IL 22950613 A IL22950613 A IL 22950613A IL 229506 B IL229506 B IL 229506B
Authority
IL
Israel
Prior art keywords
dry powder
associated methods
vancomycin compositions
powder vancomycin
compositions
Prior art date
Application number
IL229506A
Other languages
Hebrew (he)
Other versions
IL229506A0 (en
Original Assignee
Savara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savara Inc filed Critical Savara Inc
Publication of IL229506A0 publication Critical patent/IL229506A0/en
Publication of IL229506B publication Critical patent/IL229506B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL229506A 2011-05-19 2013-11-19 Dry powder vancomycin compositions and associated methods IL229506B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487971P 2011-05-19 2011-05-19
PCT/US2012/038775 WO2012159103A1 (en) 2011-05-19 2012-05-21 Dry powder vancomycin compositions and associated methods

Publications (2)

Publication Number Publication Date
IL229506A0 IL229506A0 (en) 2014-01-30
IL229506B true IL229506B (en) 2019-07-31

Family

ID=47177374

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229506A IL229506B (en) 2011-05-19 2013-11-19 Dry powder vancomycin compositions and associated methods

Country Status (11)

Country Link
EP (1) EP2709646A4 (en)
JP (1) JP6012716B2 (en)
KR (1) KR101763195B1 (en)
CN (1) CN103717231B (en)
AU (1) AU2012254999B2 (en)
BR (1) BR112013029803B1 (en)
CA (2) CA2836643C (en)
IL (1) IL229506B (en)
MX (1) MX346244B (en)
SG (1) SG195038A1 (en)
WO (1) WO2012159103A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5324223B2 (en) 2005-12-08 2013-10-23 トランセイブ, インク. Lipid-based compositions of anti-infectives for treating pulmonary infections and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
EP2925298B1 (en) 2012-11-29 2019-05-29 Insmed Incorporated Stabilized vancomycin formulations
CA2897651C (en) 2013-01-10 2021-09-21 Pulmokine, Inc. Non-selective kinase inhibitors
CN104043104B (en) * 2013-03-15 2018-07-10 浙江创新生物有限公司 The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin
CN111743901B (en) * 2013-10-11 2023-09-12 普尔莫凯恩股份有限公司 Spray-dried formulations
CN106029079A (en) * 2014-02-28 2016-10-12 阿尔吉法玛公司 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
CA2941867A1 (en) 2014-03-14 2015-09-17 Cutispharma, Inc. Composition and method for vancomycin oral liquid
RS60827B1 (en) 2014-05-15 2020-10-30 Insmed Inc Methods for treating pulmonary non-tuberculous mycobacterial infections
SI3542812T1 (en) 2014-11-06 2021-04-30 Xellia Pharmaceuticals Aps Glycopeptide compositions
CA2974220C (en) 2015-02-06 2023-05-16 Latitude Pharmaceuticals, Inc. Aqueous solution formulations of vancomycin
GB201609940D0 (en) 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
WO2018081567A1 (en) 2016-10-27 2018-05-03 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
CN106963939A (en) * 2017-03-22 2017-07-21 永信药品工业(昆山)股份有限公司 Vancomycin hydrochloride pharmaceutical composition and preparation method thereof
CA3062570A1 (en) * 2017-05-22 2018-11-29 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3866829A1 (en) * 2018-10-15 2021-08-25 Savara Inc. Separation of vancomycin and its degradation products

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
ZW21483A1 (en) 1982-10-08 1985-05-08 Glaxo Group Ltd Device for administering medicaments to patients
NO166268C (en) 1985-07-30 1991-07-03 Glaxo Group Ltd DEVICE FOR ADMINISTRATING PATIENTS TO PATIENTS.
JPH03193735A (en) * 1989-12-22 1991-08-23 Shionogi & Co Ltd Stabilized composition of glycopeptide-based antibiotic
JPH05963A (en) 1990-04-13 1993-01-08 Toray Ind Inc Polypeptide composition
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP4142149B2 (en) * 1997-07-10 2008-08-27 明治製菓株式会社 Vancomycin lyophilized formulation
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
AU775565B2 (en) * 1999-10-29 2004-08-05 Novartis Ag Dry powder compositions having improved dispersivity
JP4837892B2 (en) * 2001-11-01 2011-12-14 ネクター セラピューティクス Method for producing powder batch
DE10358387A1 (en) * 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder containing low molecular weight dextran and process for their preparation
FR2872044B1 (en) * 2004-06-28 2007-06-29 Flamel Technologies Sa PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
LT2344129T (en) * 2008-10-07 2018-05-10 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
AU2010229721A1 (en) * 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
KR101639098B1 (en) * 2009-03-26 2016-07-12 풀매트릭스 오퍼레이팅 컴퍼니, 인크 Dry powder formulations and methods for treating pulmonary diseases

Also Published As

Publication number Publication date
CA2836643A1 (en) 2012-11-22
JP2014515356A (en) 2014-06-30
IL229506A0 (en) 2014-01-30
CA2836643C (en) 2017-11-14
JP6012716B2 (en) 2016-10-25
WO2012159103A1 (en) 2012-11-22
KR101763195B1 (en) 2017-07-31
BR112013029803B1 (en) 2021-07-13
KR20140032450A (en) 2014-03-14
EP2709646A1 (en) 2014-03-26
MX346244B (en) 2017-03-13
CA2981038C (en) 2018-09-25
CA2981038A1 (en) 2012-11-22
SG195038A1 (en) 2013-12-30
NZ618002A (en) 2015-03-27
EP2709646A4 (en) 2015-05-13
CN103717231B (en) 2016-08-17
MX2013013503A (en) 2014-05-12
AU2012254999B2 (en) 2016-02-11
BR112013029803A2 (en) 2017-01-17
CN103717231A (en) 2014-04-09
NZ704819A (en) 2016-05-27

Similar Documents

Publication Publication Date Title
IL229506B (en) Dry powder vancomycin compositions and associated methods
HK1199694A1 (en) Probiotic compositions and methods
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2591359A4 (en) Methods and compositions for quantifying exosomes
EP2624702A4 (en) Anti-biofilm compositions and methods for using
ZA201306316B (en) Methods and compositions for preparing noribogaine from voacangine
EP2691397A4 (en) Methods and compositions for preparing noribogaine from voacangine
EP2629742A4 (en) Hair-mending compositions and associated methods
GB201102237D0 (en) Particle formulation
ZA201304201B (en) Composition comprising insecticide-wax particles
EP2854530A4 (en) Compositions and methods for -glucan immunotherapy
EP2785176A4 (en) Anti-microbial compositions and related methods
EP2555788A4 (en) Methods and compositions for cardioprotection and cardioregeneration
IL250307A0 (en) Fumigant compositions and methods
GB201315350D0 (en) Methods and compositions
ZA201304122B (en) Methods and compositions for drying coal
EP2762129A4 (en) Cosmetic composition and cosmetic
GB201315347D0 (en) Methods and compositions
HK1201451A1 (en) Compositions and methods
EP2575869A4 (en) Peptide particle formulation
EP2668044A4 (en) Compositions and their use
GB201018650D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
EP2766357A4 (en) Meso-biliverdin compositions and methods
GB201106357D0 (en) Composition and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed